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OUTCOMES OF EXTENDED-INFUSION PIPERACILLIN/TAZOBACTAM IN 
PEDIATRIC PATIENTS
Kristen R Nichols, PharmD; Katie Andricopulos, PharmD; Ashley S Crumby, PharmD; 
Elaine G Cox, MD; Chad A Knoderer, PharmD
Butler University College of Pharmacy and Health Sciences,
Riley Hospital for Children at Indiana University Health, and Indiana University School of Medicine, 
Indianapolis, Indiana
BACKGROUND
 Piperacillin/tazobactam (PT) bactericidal activity 
associated with fT > MIC
 Improve fT > MIC through use of continuous or 
extended infusions (EI)
 Data in pediatric patients are limited 
 Courter et al4 simulated extended and continuous infusion 
PT dosing regimens 
 PK data from healthy 2 & 12 year olds
 337.5 mg/kg/day divided Q8H, infused over 3 hours 
provides 98% PTA for MICs up to 8 mg/L
 Since 2011, standard of care for PT dosing at Riley 
Hospital for Children is 112.5 mg/kg IV Q8H, infused over 
4 hours5 
 Prior to 2011, standard of care was 84.4 mg/kg IVq6H 
infused over 30 minutes
 To determine the impact of an extended-infusion PT 
dosing regimen, as compared to a traditional dosing 
regimen, on outcomes in children with gram-negative 
infections
Design Outcomes
Lodise
20071
-Retrospective 1-center review
- Adults with P. aeruginosa
infection
-Traditional PT vs EIPT
-Pts with APACHE-II ≥ 17 
had ↓mortality (31.6% vs
12.2%, p=0.04) and ↓ LOS 
(38 vs 21 days, p=0.02)
Patel 
20092
-Retrospective 2-center review
-Adults with GNR infection
-Traditional PT vs EIPT
-Mortality similar between 
groups (5.7% vs 8.5%, 
p=0.54)
-LOS similar
Yost
20113
-Retrospective multi-center 
review
-Adults with GNR infection
-EIPT vs non-EI β-lactam
comparators
-In-hospital mortality ↓ in 
EIPT group (9.7 vs 17.9%, 
p=0.02)
-Multivariate analysis; 
mortality OR 0.43, p=0.05
STUDY OBJECTIVE
METHODS
 Retrospective chart review (April 2010 – March 2012)                                       
 Inclusion:
 Inpatients with ages 1 month – 17 years
 Documented gram-negative infection 
 Received PT for ≥ 48 hours
 Exclusion:
 Prior to study regimen, received another PT dosage 
regimen or more than one dose of another β-lactam 
with similar activity
 Concurrent inadequate treatment of gram positive or 
fungal pathogens
 NICU admission
 RRT
Traditional PT
84.4 mg/kg IV q6H 
infused over 30 min
EIPT
112.5 mg/kg IV q8H 
infused over 4 hrs
Primary
21-day 
clinical 
cure
Symptomatic resolution, afebrile, WBC 
normal, negative f/u cultures if available
Secondary
Length of hospital stay (LOS)
Duration of PT therapy (DOT)
30-day mortality
30-day readmission
≥ 50% increase in SCr from baseline
RESULTS
RESULTS
 85 patients included (1004 screened)
Traditional PT EIPT p
n 35 50
Male % (n) 60 (21) 42 (21) 0.102
Age, mos – median (IQR) 36(17-132) 84(24-132) 0.22
Weight, kg – median (IQR) 14.8(9.6-38.6) 22.6(13-37.4) 0.233
Cystic Fibrosis % (n) 8.6 (3) 22 (11) 0.1
CONCLUSION
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Traditional PT EIPT p
21-day cure %(n) 85.7 (30) 74 (37) 0.193
LOS, days
median (IQR) 11 (7-22) 11.5 (5.75-22.5) 0.844
DOT, days
median (IQR) 8 (4-14) 5 (3-8.25) 0.07
30-day readmission 34.3 (12) 32 (16) 0.825
↑ SCr 5.7 (2) 10 (5) 0.479
 No 30-day mortality in either group
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Table 1. Clinical outcomes in adults receiving EIPT (4 hour infusion) 
Table 3. Baseline characteristics
Table 4. Outcome comparison between traditional and EIPT
Figure 1. Culture sites in traditional and EIPT groups
Table 2. Evaluated outcomes 
vs
